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Exercise testing has an established role in the evaluation of patients with valvular heart disease and can aid clin-
ical decision making. Because symptoms may develop slowly and indolently in chronic valve diseases and are
often not recognized by patients and their physicians, the symptomatic, blood pressure, and electrocardiographic
responses to exercise can help identify patients who would benefit from early valve repair or replacement. In
addition, stress echocardiography has emerged as an important component of stress testing in patients with
valvular heart disease, with relevant established and potential applications. Stress echocardiography has the
advantages of its wide availability, low cost, and versatility for the assessment of disease severity. The versatile
applications of stress echocardiography can be tailored to the individual patient with aortic or mitral valve dis-
ease, both before and after valve replacement or repair. Hence, exercise-induced changes in valve hemodynam-
ics, ventricular function, and pulmonary artery pressure, together with exercise capacity and symptomatic re-
sponses to exercise, provide the clinician with diagnostic and prognostic information that can contribute to
subsequent clinical decisions. Nevertheless, there is a lack of convincing evidence that the results of stress echo-
cardiography lead to clinical decisions that result in better outcomes, and therefore large-scale prospective ran-
domized studies focusing on patient outcomes are needed in the future. (J Am Coll Cardiol 2009;54:2251–60)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.046f
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bdvances in diagnosis and risk stratification, combined with
teady progress in surgical valve replacement and repair,
ave led to improved outcomes of patients with valvular
eart disease over the past 5 decades. The most important
ndication for surgical intervention in patients with hemo-
ynamically significant aortic or mitral valve disease is the
evelopment of symptoms, as emphasized in recent guide-
ines (1,2). Because symptoms may develop slowly and
ndolently in these chronic conditions, many patients are
naware of subtle changes in effort tolerance, even when
uestioned directly by their physicians. Hence, guidelines of
oth the American College of Cardiology/American Heart
ssociation (ACC/AHA) and the European Society of
ardiology (ESC) (1,2) have placed renewed emphasis on
he role of exercise testing to provide objective evidence of
xercise capacity and symptom status. In addition, although
oppler echocardiography at rest is the method of choice
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ccepted July 28, 2009.or assessing severity of valvular disease, there is a growing
se of stress 2-dimensional and Doppler echocardiography
o assess dynamic changes in hemodynamics in concert with
he clinical findings of exercise testing.
Stress echocardiography is well established for evaluating
atients with coronary artery disease (CAD) (3–5). The role
f stress echocardiography for the assessment of the hemo-
ynamic consequences of valvular lesions was initially pro-
osed in the 1980s (6,7) but only recently gained recogni-
ion by specialized and general guidelines (1,2,8,9). In a
umber of patients with valvular heart disease, particularly
hose with low-flow, low-gradient aortic valve stenosis
AS), stress echocardiography provides additional informa-
ion regarding severity of disease and hence aids in risk
tratification and clinical decision making.
The majority of the recommendations in the guidelines
o not have an extensive evidence base, underscoring the
eed for more clinical investigation in this area. In valvular
eart disease, exercise testing is preferred over pharmaco-
ogical stress because it provides insights regarding exer-
ional symptoms and blood pressure responses. The excep-
ion is the use of pharmacologic stress echocardiography in
atients with low-flow, low-gradient AS. Supine bicycle
xercise is recommended because Doppler information can
e obtained during the different stages of exercise (8,9),
ather than post-treadmill imaging, when there are substan-
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Stress Testing in Valve Disease December 8, 2009:2251–60tial and rapid changes in heart
rate and loading conditions. On
the other hand, supine exercise is
not as physiologic as is treadmill
exercise, and the equipment is
not nearly as widely available as is
the treadmill.
AS
Asymptomatic patients with
severe AS. The onset of symp-
toms in patients with severe AS
represents a clear indication for
aortic valve replacement (AVR)
(1,2). Exercise testing clearly has
no role, and is contraindicated in
patients with definite cardiac
symptoms or symptoms that are
highly suspicious. On the other
hand, it is apparent that some
patients, especially elderly pa-
tients, may ignore or not report
ild dyspnea and fatigue, which are difficult to differentiate
rom the effects of aging or deconditioning. Patients also
ay reduce their level of physical activity to avoid or
inimize symptoms. The principal role of exercise testing is
o unmask symptoms or abnormal blood pressure responses
n patients with AS who claim to be asymptomatic.
Numerous studies have shown that exercise testing, with
ppropriate physician supervision and close monitoring of
he electrocardiogram and blood pressure, is safe in patients
ithout apparent symptoms (10–15) and that the results
an identify a subset of patients with a high likelihood of
eath or symptom onset over the next 1 to 2 years (13–15).
oth the ACC/AHA and the ESC guidelines (1,2) support
he role of exercise testing in asymptomatic AS patients,
ith recommendations that AVR be considered in those
ith exercise-induced symptoms or abnormal blood pres-
ure responses. The strength of this recommendation differs
etween the 2 guidelines, with a Class IIb recommendation
rom the ACC/AHA compared with Class I (symptoms)
nd Class IIa (abnormal blood pressure) recommendations
rom the ESC. The divergent strengths of these recommen-
ations arise from the lack of definitive evidence from
rospective clinical trials and the consensus of 2 different
riting groups in interpreting the available data. For exam-
le, it is often difficult to ascertain in aging and decondi-
ioned patients with AS whether symptoms on treadmill
esting truly represent cardiac symptoms. In addition, phy-
icians may have a lower threshold for referring a patient for
VR after a treadmill test in which the patient had
mpaired exercise tolerance, presumed symptoms, or an
bnormal blood pressure response compared with patients
ith excellent exercise capacity and a normal blood pressure
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
AR  aortic regurgitation
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve
replacement
CAD  coronary artery
disease
ESC  European Society of
Cardiology
LV  left ventricular
MR  mitral regurgitation
MS  mitral stenosis
MVA  mitral valve area
PPM  valve prosthesis–
patient mismatchesponse. This could result in a post-test referral bias in etudies of exercise testing in AS, in which patients with
bnormal exercise results are preferentially referred to AVR.
The role of exercise echocardiography in asymptomatic
atients with AS is less clear because this has not been
tudied extensively (16,17). A recent study (17) investigat-
ng 69 asymptomatic patients with severe AS (aortic valve
rea [AVA] 1.0 cm2) has shown that an increase in the
ean aortic valve pressure gradient of 18 mm Hg or more
uring exercise was an independent predictor of symptom
nset during the 15-month mean follow-up period, as were
n AVA 0.75 cm2 and abnormal exercise results (symp-
oms, ST-segment depression, or 20 mm Hg increase in
lood pressure). This increase in mean pressure gradient
uring exercise reflects the presence of fixed valve stenosis
ith limited valve compliance (18). Stress echocardiography
lso provides assessment of the LV functional response to
xercise (19,20), with evidence suggesting that patients with
imited LV functional reserve (those with a lower increase in
jection fraction) are at increased risk for untoward events
20). Whether an increase in the mean aortic valve pressure
radient and/or a limited increase in ejection fraction should
e considered criteria for early elective surgery requires
dditional investigation.
ortic valve stenosis with low-flow, low-gradient, and
V dysfunction. In contrast to patients with severe AS and
reserved LV function, there seems to be a well-defined role
f stress echocardiography in patients with LV dysfunction
21–27) (Fig. 1). Patients with anatomically severe AS and
V systolic dysfunction (ejection fraction 40%) often
resent with a relatively low-pressure gradient, such as a
ean gradient of 30 to 40 mm Hg or less. These patients
epresent a diagnostic challenge because it is often difficult
o differentiate them from other patients with a primary
ardiomyopathic process and a thickened but nonstenotic
ortic valve producing an outflow murmur. This latter
ondition is often termed pseudosevere AS. In true severe
S, the small and relatively fixed AVA contributes to an
ncrease in afterload, a decrease in ejection fraction, and a
eduction stroke volume. In pseudosevere AS, the predom-
nant factor is myocardial disease, and the severity of AS is
verestimated on the basis of AVA because there is incom-
lete opening of the valve caused by reduction in the
pening force generated by the weakened ventricle. In both
ituations, the low-flow state and low-pressure gradient
ontribute to a calculated AVA that meets criteria for severe
S at rest (1.0 cm2) (Fig. 1). Hence, the resting echocar-
iogram does not distinguish between these 2 situations.
et, this distinction is essential because patients with true
evere AS and poor LV function will generally benefit
ignificantly from AVR, whereas the patients with pseudo-
evere AS will not and may also have a higher risk of
erioperative mortality.
The main objective of dobutamine stress echocardiogra-
hy in the context of low-flow AS is to increase the
ransvalvular flow rate while not inducing myocardial isch-
mia. Side effects are not infrequent with full-dose dobut-
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December 8, 2009:2251–60 Stress Testing in Valve Diseasemine in unselected patients with normal or moderately
educed LV ejection fraction (9,28) and can occur in up to
0% of patients with low-flow, low-gradient AS (29).
rrhythmias are the most frequent serious adverse reactions.
achyarrhythmias (including ventricular fibrillation) can
rise from ischemia or ischemia-independent direct arrhyth-
ogenic effects of adrenergic stimulation, and brady-
rrhythmias (including cardiac asystole) can result from a
asodepressor reflex triggered by LV mechanoreceptor stim-
lation. Both mechanisms are magnified by LV hypertrophy
28,29). Hence, a low-dose protocol (i.e., up to 20 g/kg/
in) should be used in these patients. Moreover, it is
referable to use longer dobutamine stages (5 to 8 min
nstead of the 3 to 5 min generally used for the detection of
schemic heart disease) to ensure that the patient is in a
teady-state condition during Doppler echocardiography
Figure 1 Decision Making in Low-Flow, Low-Gradient AS
The results of dobutamine stress echocardiography aid in decision making in patie
agement decisions are more difficult when contractile reserve is absent. Contracti
Nishimura et al. (24) and Monin et al. (25). When contractile reserve is elicited, p
(P) with a low calculated aortic valve area (AVA). One can also determine the pro
ered an indicator of true severe stenosis (30). Figure illustration by Rob Flewell. Aata acquisition and before proceeding to the next stage. ahe gradual increments in dobutamine dose are also helpful
n preventing rapid increases in heart rate that may predis-
ose to myocardial ischemia, because ischemic myocardial
ysfunction may override the inotropic effect, thereby lim-
ting the increase in transvalvular flow.
The dobutamine stress approach is based on the concept
hat patients who have pseudosevere AS will show an
ncrease in the AVA and little change in the transvalvular
radient in response to the increase in transvalvular flow rate
21) (Fig. 1). Although the dichotomization of patients into
categories (true severe or pseudosevere AS) is convenient,
t is an oversimplification, and the classification of the
ndividual patient may not always be straightforward. The
hanges in gradient and AVA during dobutamine stress
epend largely on the magnitude of the flow augmentation
chieved, which may vary considerably from one patient to
th low-flow aortic stenosis (AS) when dobutamine elicits contractile reserve. Man-
rve is defined as an increase in stroke volume (SV) 20% using the criteria of
with true severe AS manifest an increase in transvalvular pressure gradient
AVA at a standardized normal flow rate (AVAProj). An AVAProj 1.0 cm
2 is consid-
ortic valve replacement; CABG  coronary artery bypass graft surgery.nts wi
le rese
atients
jected
VR  another. Therefore, the AVA and gradient are measured at
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Stress Testing in Valve Disease December 8, 2009:2251–60ow conditions that may differ dramatically from one
atient to another, and the use of these indexes, which are
ot normalized with respect to the flow increase, may lead
o misclassification of stenosis severity in some patients. To
vercome this limitation, the investigators of the TOPAS
Truly or Pseudo Severe Aortic Stenosis) multicenter study
30) have proposed a new echocardiographic parameter: the
rojected AVA at a standardized normal flow rate. A
rojected AVA 1.0 cm2 is considered an indicator of true
evere stenosis (Fig. 1) (30).
ssessment of functional reserve. Patients identified as
aving true severe AS and functional reserve, defined as the
bility to increase stroke volume with dobutamine by 20% or
ore (25), have a much better outcome with AVR than
ith medical therapy (26,27). Patients with a lack of LV
unctional reserve have been shown to have a poor prognosis
ith either medical or surgical management (25), but as a
roup they may also benefit from AVR (27,31). In other
ords, once true severe AS has been documented, AVR
ight be reasonable even in the absence of LV functional
eserve, although decisions in these high-risk patients must
e individualized in the absence of clear guidelines.
In patients with low-flow, low-gradient AS, dobutamine
tress echocardiography has received a Class IIa recommen-
ation in the ACC/AHA guidelines, with Level of Evi-
ence: B (1). This recommendation comes with the caveat
hat dobutamine stress testing in patients with AS should be
erformed only in centers with experience in pharmacolog-
cal stress testing and with an experienced cardiologist in
ttendance.
ssessment of CAD and hibernating myocardium. The
ther potential role of dobutamine stress echocardiography
n patients with AS and impaired LV function is the
etection of underlying CAD, because infarcted or hiber-
ating myocardium may be responsible in large part for the
ontractile dysfunction in many patients. In such patients,
evascularization has the potential to improve LV function
nd clinical outcomes (32,33). However, this situation can
epresent a diagnostic challenge in patients with AS because
ultivessel CAD may induce global LV dysfunction, and
onversely, regional wall motion abnormalities may occur in
he absence of CAD (34). Moreover, lack of contractile
eserve on dobutamine stress echocardiography may also be
elated to LV afterload mismatch, independent of the
resence of CAD. These factors may explain why an
mportant proportion of patients with no contractile reserve
onetheless show an improvement in LV ejection fraction
fter aortic valve replacement with or without revasculariza-
ion (27). The specificity of stress-induced ST-segment
hanges and reversible perfusion abnormalities for predict-
ng epicardial coronary artery stenosis is very low in patients
ith AS because alterations in coronary flow reserve linked
o LV hypertrophy and microvascular disease may be
resent independent of CAD at the epicardial level (35).
hus, in these complex patients coronary angiographyinvasive or noninvasive) remains the diagnostic standard. fortic Regurgitation (AR)
he development of symptoms has important prognostic
mplications in patients with AR. Natural history studies
ndicate that symptomatic patients have an excessive mor-
ality rate compared with asymptomatic patients (36), and
he severity of pre-operative symptoms is a strong determi-
ant of survival after AVR (37). As with patients with AS,
xercise testing may elicit symptomatic responses in patients
ith AR who are apparently asymptomatic based on the
edical history, thus identifying candidates for surgery. In
ddition, pre-operative exercise capacity in patients with AR
nd LV systolic dysfunction, together with duration of
re-operative LV dysfunction, is helpful in predicting sur-
ival and recovery of function after AVR (38).
The additional value of stress imaging in patients with
R is unclear. The observed magnitude of change in
jection fraction or stroke volume from rest to exercise is
elated not only to myocardial contractile function but also
o severity of volume-overload and exercise-induced
hanges in pre-load and peripheral resistance (1). The
alidity of stress echocardiography in predicting outcome of
atients with asymptomatic AR is limited by the small
umber of available studies (39,40) compared with the more
xtensive and consistent experience with exercise radionu-
lide angiography (41–44). With the sparse data supporting
he incremental prognostic value of stress echocardiography,
his specific application is not recommended for routine
linical use (1).
itral Stenosis (MS)
resting transthoracic echocardiogram is usually sufficient
o guide management in asymptomatic patients with mild to
oderate MS and in symptomatic patients with severe MS
ho are candidates for either percutaneous balloon valvulo-
lasty or surgical mitral valve repair or replacement. Man-
gement considerations are less clear in asymptomatic pa-
ients with severe MS and in symptomatic patients with
nly mild to moderate MS at rest, and in these 2 groups of
atients exercise testing can provide critical information on
unctional capacity and exercise-induced symptoms. Stress
chocardiography provides added value when more detailed
ssessment of valve function and its hemodynamic conse-
uences is needed, particularly in the asymptomatic patient
nd the patient in whom symptoms and Doppler findings at
est are discordant.
In asymptomatic patients with severe MS (mean gradient
10 mm Hg and mitral valve area [MVA] 1.0 cm2), or
ymptomatic patients with moderate MS (mean gradient of
to 10 mm Hg and MVA of 1.0 to 1.5 cm2), the
easurement of pulmonary artery pressures (measured from
he tricuspid regurgitant velocity) during exercise or dobut-
mine stress echocardiography can help distinguish those
ho could benefit from valvuloplasty or valve replacementrom those who should be maintained on medical therapy
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December 8, 2009:2251–60 Stress Testing in Valve Disease1,45,46). As is the case with the aortic valve, the transmi-
ral valve pressure gradient is related to the MVA. However,
t should be emphasized that the transmitral gradient is
uch more sensitive to heart rate than is the transaortic
radient and that the degree of this heart rate sensitivity
ay vary extensively from one patient to another. Moreover,
or a given MVA, patients with reduced atrioventricular
ompliance show a more pronounced increase in pulmonary
rterial pressure during exercise or dobutamine than those
ith normal compliance (45,47). Hence, in some patients
etermined to have only moderate MS at rest, the physio-
ogic effects of heart rate sensitivity and atrioventricular
ompliance can produce exercise-induced pulmonary hyper-
ension and exertional dyspnea. Because the resting values of
ransmitral gradient and pulmonary arterial pressure do not
ecessarily reflect the actual severity of the disease, stress
chocardiography may provide the necessary clues in deter-
ining the severity of MS, assessing its hemodynamic
mpact, and explaining exercise-induced symptoms.
The current ACC/AHA guidelines have given a Class I
ecommendation (Level of Evidence: C) for stress echocar-
iography in patients with MS and discordance between
ymptoms and stenosis severity (1). The threshold values
roposed by the ACC/AHA guidelines (1) for consider-
tion for intervention are a mean transmitral pressure
radient 15 mm Hg during exercise or a peak pulmonary
rtery systolic pressure60 mm Hg during exercise (Fig. 2).
n patients with pulmonary artery pressures or valve gradi-
nts above these values, percutaneous balloon valvotomy or
urgical intervention is recommended, even for patients
ith apparently moderate MS at rest (1,7,9). There are
mportant caveats in applying these recommendations in
linical practice because they are all based on a level C
eight of evidence, and the proposed cutoff values remain
rbitrary and consensus driven and not supported by evi-
ence of improved outcomes. Therefore, this represents
nother area in which further clinical research is needed.
itral Regurgitation (MR)
egenerative MR. The severity of degenerative MR can
e reliably assessed by resting color-flow Doppler echocar-
iography with the use of semiquantitative or quantitative
ethods (1,2,48). Such information is useful to predict the
evelopment of LV dysfunction and of symptoms (49).
resently, there is an important ongoing controversy regard-
ng whether asymptomatic patients with severe MR should
ndergo early elective mitral valve repair (49–52). In se-
ected patients with MR, exercise testing may aid in this
ritical management decision.
Exercise capacity itself is a predictor of the development
f symptoms or LV dysfunction in asymptomatic patients
ith MR (53). In asymptomatic patients with severe MR,
xercise stress echocardiography may help identify patients
ith unrecognized symptoms or subclinical latent LV dys-unction. tIn symptomatic patients in whom the severity of MR is
stimated to be only mild at rest, exercise echocardiography
ay be useful in elucidating the cause of symptoms by
etermining whether the severity of MR increases or pul-
onary arterial hypertension develops during exercise (54).
t is noteworthy that the data supporting this concept were
erived in patients with rheumatic MR, and the data
upporting this application for degenerative MR are limited.
oreover, data supporting this application in asymptomatic
atients are limited. However, worsening of MR severity, a
arked increase in pulmonary arterial pressure, impaired
xercise capacity, and the occurrence of symptoms during
xercise echocardiography can be useful findings for identi-
ying a subset of apparently asymptomatic patients at higher
isk who may benefit from early surgery. A pulmonary artery
ystolic pressure 60 mm Hg during exercise has been
uggested as a threshold value above which asymptomatic
atients with severe MR might be referred for surgical valve
epair (1,8). This application of stress echocardiography is
ated as a Class IIa recommendation with Level of Evi-
ence: C (1). Recommendations for early surgery in asymp-
Figure 2 Exercise Echocardiography in Mitral Stenosis
This symptomatic patient has only moderate mitral stenosis determined at
rest, with a mitral valve area of 1.2 cm2 and mean transmitral pressure gradi-
ent (Pmean) of 5 mm Hg. However, with exercise, there is a marked increase
in the transmitral gradient and systolic pulmonary arterial pressure as
assessed by the transtricuspid pressure gradient (TTPG). In this patient, the
exercise-induced increase in mean transvalvular flow rate (Qmean) and transmi-
tral gradient was caused by the dramatic shortening in diastolic filling time
(DFT), thus providing a mechanism for the patient’s symptoms. HR  heart
rate; SV  stroke volume.omatic patients should only be made in those patients who
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Stress Testing in Valve Disease December 8, 2009:2251–60re candidates for mitral valve repair and in experienced
enters in which there is expertise both in noninvasive
valuation and in surgical correction, with a high likelihood
90%) of successful mitral repair without residual MR (1).
alve replacement has particularly serious negative conse-
uences for asymptomatic patients. Large prospective stud-
es are needed to establish the usefulness of stress echocar-
iography for risk stratification and clinical decision making
n degenerative MR.
The spectrum of LV responses to exercise stress in
atients with MR is not dissimilar to that described for
atients with AR (55), but the prognostic impact of this
unctional heterogeneity remains unsettled, and the impor-
ance of LV functional reserve in MR as assessed by changes
n LV ejection fraction remains to be defined. A recent report,
sing 2-dimensional speckle tracking of myocardial deforma-
ion, has shown that reduced LV longitudinal functional
eserve with exercise predicts midterm impairment in LV
unction in medically-treated patients with MR as well as
ost-operative LV dysfunction in patients who have undergone
urgery for MR (56). This novel application of stress echocar-
iography is the subject of ongoing investigation.
schemic MR. MR is a common feature of ischemic LV
ystolic dysfunction (57–59). Patients with ischemic MR
ave more severe LV dysfunction compared with patients
ithout associated MR, and the available data indicate that
R also confers a greater mortality risk and a greater risk of
Figure 3 Exercise Echocardiography in Ischemic Mitral Regurg
Apical 4-chamber views of color-flow Doppler and proximal flow-convergence region
the systolic tricuspid regurgitation velocity (right panel). With exercise, there is a
artery systolic pressure. ERO  effective regurgitant orifice measured by the proxim
pid pressure gradient.eveloping overt heart failure (57–60). MR arises in chronic
AD from global and regional LV remodeling (apical and
osterior displacement of papillary muscles) leading to
apillary muscle displacement, tenting of the mitral valve
eaflets, and loss of systolic annular contraction (61–63).
ence, ischemic MR is primarily a disease of the LV
yocardium, and therapies that produce beneficial reverse
V remodeling, such as myocardial revascularization (64),
eta-blocker therapy (65), and cardiac resynchronization
66–68), have the potential to reduce or eliminate MR. In
he case of revascularization, this can usually only be
chieved with concomitant mitral valve repair with restric-
ive annuloplasty or mitral valve replacement (1,2,69,70).
A principal role of stress echocardiography in ischemic
R is to determine the extent of dysfunctional but viable
ibernating myocardium. Identification of viable myocar-
ium with pharmacologic stress echocardiography predicts
he likelihood of recovery of function and beneficial reverse
emodeling with revascularization (64,71–73), beta-blockade
74), and cardiac resynchronization therapy (75). Changes
n MR severity can also be observed during dobutamine
tress testing for myocardial viability, but the direct effect of
obutamine on loading conditions is a major confounding
ariable. Moreover, the role of surgical intervention targeted
o eliminate MR remains uncertain because there is a high
ate of recurrent MR related to ongoing LV remodeling
76), and long-term survival of patients with ischemic MR
n
anels) are shown in a patient with ischemic mitral regurgitation (MR) along with
increase in both the severity of mitral regurgitation and the estimated pulmonary
velocity surface area; R Vol  regurgitant volume; TTPG  systolic transtricus-itatio
(left p
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December 8, 2009:2251–60 Stress Testing in Valve Diseases poor whether treated medically or surgically (77,78), in
arge part related to the severity of LV dysfunction.
The role of Doppler echocardiography in assessing dy-
amic changes in MR severity with exercise, to identify
igher-risk patients for surgery, is the subject of current
nvestigation. The magnitude of ischemic MR varies dy-
amically in accordance with changes in loading conditions,
V regional wall motion, and annular size and the balance
f tethering versus closing forces applied on the mitral valve
eaflets (79). Hence, the severity of MR assessed by Doppler
chocardiography at rest does not necessarily reflect the
everity of MR that develops during exercise. Exercise stress
chocardiography has been shown to unmask hemodynam-
cally significant MR in patients with ischemic LV systolic
ysfunction and only mild to moderate MR at rest (Fig. 3),
nd in doing so to identify patients at higher risk for heart
ailure and death (80–82). The magnitude of increase in
ffective regurgitant orifice during exercise often cannot be
redicted from the resting effective regurgitant orifice.
Pierard and Lancellotti (82,83) have proposed that exer-
ise Doppler echocardiography can provide useful informa-
ion in the following patients with ischemic MR: 1) those
ith exertional dyspnea out of proportion to the severity of
R or the degree of LV dysfunction at rest; 2) those in
hom acute pulmonary edema occurs without an obvious
ause; and 3) those with moderate MR before surgical
evascularization. A large prospective multicenter registry of
urgery in patients with ischemic MR is underway, designed
o assess the role of exercise echocardiography in identifying
eterminants of adverse outcomes, progressive LV remod-
ling, and efficacy of treatment (84).
rosthetic Heart Valves
chocardiography is the method of choice for evaluating
rosthetic valve function (1,2). Because most prosthetic
alves are inherently stenotic, the effective orifice area of a
rosthetic valve is occasionally too small in relation to body
ize, a phenomenon known as valve prosthesis–patient
ismatch (PPM) (85,86). In the aortic position, PPM is
onsidered moderate when the indexed effective orifice area
s 0.85 cm2/m2 and severe when it is 0.65 cm2/m2 (87).
n the mitral position, the cutoff values are 1.2 and 0.9
m2/m2, respectively. PPM has been linked to impaired
xercise capacity, suboptimal symptomatic improvement,
ncomplete regression of LV hypertrophy and pulmonary
ypertension, and increased cardiac events and mortality
88–93). PPM is a frequent cause of increased transpros-
hetic gradient (86,94). It is important to differentiate this
ondition from acquired prosthetic stenosis, which may
esult from leaflet calcification, pannus overgrowth, or
hrombus formation.
Because normally and abnormally functioning prostheses
an produce similar estimated gradients at rest by transtho-
acic echocardiography, stress echocardiography may be
aluable in confirming or excluding the presence of hemo-ynamically significant prosthetic valve stenosis or PPM,
specially when there is discordance between the patient’s
ymptomatic status and the prosthetic valve hemodynamics
easured at rest (87,95,96). In contrast to a normally
unctioning and well-matched prosthesis (including a
ileaflet mechanical valve with a localized high gradient at
est), a stenotic prosthetic valve or PPM is generally
ssociated with impaired exercise capacity and a marked
ncrease in gradient with exercise, often with pulmonary
rterial hypertension (97,98). A disproportionate increase in
ransvalvular gradient (20 mm Hg for aortic prostheses or
12 mm Hg for mitral prostheses) generally indicates severe
rosthesis dysfunction or PPM (Fig. 4). High resting and
tress gradients occur more often with smaller (21 for aortic
Figure 4 Exercise Echocardiography
and Prosthetic Heart Valves
The mean transprosthetic pressure gradients at rest and during sustained
physical exercise are shown as a function of the indexed effective orifice area
(EOA) for aortic (A) and mitral (B) prostheses. Compared with Patients #2 and
#4, who have large prosthetic EOAs, Patients #1 and #3, with small EOAs,
show a major increase in gradient with exercise, thus suggesting the presence
of severe prosthetic stenosis or valve prosthesis–patient mismatch in these
latter patients. Figure illustration by Rob Flewell.
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ismatched rather than nonmismatched prostheses.
onclusions
xercise testing has an established role in the evaluation of
atients with valvular heart disease and can aid significantly
n clinical decision making. Stress echocardiography has
merged as an important component of stress testing in
hich the noninvasive assessment of dynamic changes in
alve function, ventricular function, and hemodynamics can be
oupled with assessment of exercise capacity and symptomatic
esponses. Stress echocardiography has the advantages of its
ide availability, low cost, and versatility for the assessment of
isease severity (1,2,8,9). Hence, together with exercise capac-
ty and symptomatic responses to exercise, it provides the
linician with diagnostic and prognostic information that can
ontribute to subsequent clinical decisions.
Guidelines, restricted to the rigors of evidence-based
ata, may underemphasize the utility of exercise testing in
alve disease. Nevertheless, it is also true that most of the
uidelines and society recommendations are based on Level
f Evidence: C, that is, the consensus of the writing
ommittees in the absence of a firm evidence base (99).
onvincing evidence is lacking that the results of stress
chocardiography lead to clinical decisions that result in
etter outcomes. Prospective large-scale, and when possible,
andomized (medical vs. interventional treatment) outcome
tudies are needed at this point to support more evidence-
ased rather than consensus-based treatment strategies in
atients with valvular heart disease.
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